1. Introduction
In December 2019, an outbreak of unknown acute respiratory tract infection originated in Wuhan, China 1. Shortly after first lower respiratory tract infection cases, the World Health Organization (WHO) named this newly emerged coronavirus as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its resultant disease as coronavirus disease 2019 (Covid-19) 2, 3. Coronaviruses are a large class of viruses that often cause mild to moderate upper respiratory tract infection. However, three of them have arisen from animal sources in the past two decades, resulted in Severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) epidemics as well as the novel Covid-19 pandemic4-6.
There is evidence of increased incidence, rapid progression, and poor prognosis of Covid-19 in patients with underlying comorbidities7-9. Diabetes is a significant risk factor for hospitalization and adverse outcome in these patients10-12, as similar evidence was reported for two previous CoV infections, SARS and MERS 4, 5, 13. Moreover, several studies have suggested epilepsy as a potential risk factor to morbidity and mortality in Covid-19 patients; nevertheless, the association as of yet is unclear 14-16.
Herein, we report a confirmed case of Covid-19 patient with a history of multiple underlying diseases, including diabetes, epilepsy, and gout. The patient died a week after intensive care unit (ICU) admission. We desire to highlight recesses in the knowledge that require further studies related to Covid-19 in patients with underlying comorbidities.